Recently, several investigations showed the efficacy of active blocking of the pathway of programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) of immune checkpoint inhibitors in patients with various PD-L1-expressing cancers. The gene discussed is CD274; the disease is cancer.